Pharma Report 2012: Get Back in Shape

Share this article:
Pharma Report 2012: Get Back in Shape
Pharma Report 2012: Get Back in Shape

9    Amgen    $13.1B     up 3.1%
Global revenue: $15.6B (15th); up 3.3%

R&D spend: $3.2B (14th), up 10.3%; 20.5% of rev.

Top brands: Enbrel ($3.5B), Neulasta ($3.0B), Epogen ($2.0B), Sensipar ($518M), Xgeva ($343M)

Planned launches: AMG386 (onc.); ganitumab (onc.)

Promotional spend: $346M (15th); 2.6% of rev.

Patent expirations: Neupogen (2013), Neulasta (2015), Epogen (2015), Sensipar (2015)

Amgen has enjoyed a stable of top-earning biologic products. Over the next several years, many of the patents on these products will expire, and the company expects to face competition, including from biosimilars. Teva has already filed a BLA for a Neupogen-like biosimilar. Amgen's ESA drugs Aranesp and Epogen have also been buffeted by new CMS bundling rules and by warnings on their labels. Launches of denosumab drugs Prolia and Xgeva haven't met projections. Luckily for Amgen, top seller Enbrel shouldn't see biosimilar competition for some time—Amgen and ex-US marketing partner Pfizer just locked up protection for another 17 years. Moreover, the Enbrel co-promote expires in late 2013, after which Amgen will pocket overseas revenues for the biologic, as well.

Back to first page

Page 9 of 21
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Is your marketing strategy stuck in 2005?

Is your marketing strategy stuck in 2005?

It is not enough to just have a killer black book or Rolodex. The market needs agile, swift marketing

Is guidance stifling social media?

Recent FDA draft guidance was meant to help companies create FDA-compliant tweets and handle third-party misinformation on the web. What other obstacles lie in the path of effective social media use?

FDA social media guides draw flak

FDA social media guides draw flak

Two FDA guidance documents on how health product manufacturers may participate in social media have drawn criticism from industry and consumer groups.